Avyxa Holdings

6 products tracked · names used in filings: Avyxa Holdings, Avyxa Holdings, Llc.

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Mon 09 Nov 2026🇺🇸 FDA approval

FDA approves Oxderys (doxorubicin hydrochloride): new formulation or manufacturer

Avyxa Holdings; NDA221093; New formulation or manufacturer; vial · source

Thu 29 Oct 2026🇺🇸 FDA approval

FDA approves Axycis (cisplatin): new formulation or manufacturer

Avyxa Holdings, Llc.; NDA220748; New formulation or manufacturer; liquid · source

Wed 24 Jun 2026🇺🇸 FDA approval

FDA approves Navitrux (fosaprepitant dimeglumine): new formulation or manufacturer

Avyxa Holdings; NDA220436; New formulation or manufacturer; powder · source

Fri 20 Feb 2026🇺🇸 FDA approval

FDA approves Favlyxa (fluorouracil): new formulation or manufacturer

Avyxa Holdings; NDA220201; New formulation or manufacturer; solution · source

Fri 13 Feb 2026🇺🇸 FDA approval

FDA approves Avopef (etoposide): new dosage form

Avyxa Holdings; NDA220200; New dosage form; solution · source

Tue 03 Feb 2026🇺🇸 FDA approval

FDA approves Vykoura (leucovorin calcium): new formulation or manufacturer

Avyxa Holdings; NDA220406; New formulation or manufacturer; solution · source

Products

	Product	Status	Approved
🇺🇸	Oxderys doxorubicin hydrochloride	Approved	2026-11-09
🇺🇸	Axycis cisplatin	Approved	2026-10-29
🇺🇸	Navitrux fosaprepitant dimeglumine	Approved	2026-06-24
🇺🇸	Favlyxa fluorouracil	Approved	2026-02-20
🇺🇸	Avopef etoposide	Approved	2026-02-13
🇺🇸	Vykoura leucovorin calcium	Approved	2026-02-03

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.